American Century Companies Inc. Acquires 12,360 Shares of United Therapeutics Co. (NASDAQ:UTHR)

American Century Companies Inc. increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 42.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 41,233 shares of the biotechnology company’s stock after acquiring an additional 12,360 shares during the quarter. American Century Companies Inc.’s holdings in United Therapeutics were worth $13,135,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. ClariVest Asset Management LLC raised its holdings in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Coldstream Capital Management Inc. raised its stake in United Therapeutics by 4.0% in the second quarter. Coldstream Capital Management Inc. now owns 2,087 shares of the biotechnology company’s stock valued at $665,000 after purchasing an additional 81 shares in the last quarter. Andra AP fonden lifted its position in United Therapeutics by 5.7% during the second quarter. Andra AP fonden now owns 35,100 shares of the biotechnology company’s stock worth $11,181,000 after purchasing an additional 1,900 shares during the period. Texas Permanent School Fund Corp lifted its position in United Therapeutics by 19.0% during the second quarter. Texas Permanent School Fund Corp now owns 48,928 shares of the biotechnology company’s stock worth $15,586,000 after purchasing an additional 7,799 shares during the period. Finally, Choreo LLC acquired a new stake in United Therapeutics during the second quarter worth about $336,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent analyst reports. UBS Group lifted their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. Oppenheimer lifted their price target on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Wells Fargo & Company upped their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $353.00 on Friday. The company has a market capitalization of $15.66 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The stock has a fifty day simple moving average of $339.19 and a 200 day simple moving average of $291.68.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same quarter last year, the business earned $5.24 earnings per share. United Therapeutics’s revenue was up 19.8% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Co. will post 24.86 EPS for the current year.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 7,802 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the sale, the chief financial officer now directly owns 3,210 shares in the company, valued at $1,108,766.10. The transaction was disclosed in a filing with the SEC, which is available at this link. In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,076.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 110,922 shares of company stock worth $36,541,398. 12.50% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.